JPWO2021050692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021050692A5 JPWO2021050692A5 JP2022507861A JP2022507861A JPWO2021050692A5 JP WO2021050692 A5 JPWO2021050692 A5 JP WO2021050692A5 JP 2022507861 A JP2022507861 A JP 2022507861A JP 2022507861 A JP2022507861 A JP 2022507861A JP WO2021050692 A5 JPWO2021050692 A5 JP WO2021050692A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- eye
- affected
- symptoms
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898401P | 2019-09-10 | 2019-09-10 | |
| US62/898,401 | 2019-09-10 | ||
| PCT/US2020/050150 WO2021050692A2 (fr) | 2019-09-10 | 2020-09-10 | Procédés pour atténuer l'inquiétude associée à un ptérygion concernant l'aspect oculaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547401A JP2022547401A (ja) | 2022-11-14 |
| JPWO2021050692A5 true JPWO2021050692A5 (fr) | 2023-09-19 |
Family
ID=74870040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507861A Pending JP2022547401A (ja) | 2019-09-10 | 2020-09-10 | 翼状片に関連した眼の見た目についての心配を軽減するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220331310A1 (fr) |
| EP (1) | EP4027997A4 (fr) |
| JP (1) | JP2022547401A (fr) |
| KR (1) | KR20220061147A (fr) |
| CN (1) | CN114340618A (fr) |
| AU (1) | AU2020346812A1 (fr) |
| BR (1) | BR112021026662A2 (fr) |
| CA (1) | CA3146811A1 (fr) |
| MX (1) | MX2022000468A (fr) |
| WO (1) | WO2021050692A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018014869A (es) | 2016-06-02 | 2019-09-13 | Cloudbreak Therapeutics Llc | Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100185564A1 (en) * | 2009-01-21 | 2010-07-22 | Mccormick & Company, Inc. | Method and questionnaire for measuring consumer emotions associated with products |
| WO2013188268A1 (fr) * | 2012-06-12 | 2013-12-19 | Bayer Healthcare Llc | Composition pharmaceutique ophtalmique topique contenant du pazopanib |
| US8747852B1 (en) * | 2012-12-28 | 2014-06-10 | Randal Tanh Hoang Pham | Methods of treating pterygium |
| ES2971096T3 (es) * | 2015-06-06 | 2024-06-03 | Cloudbreak Therapeutics Llc | Composiciones y métodos para tratar el terigio |
| PE20180252A1 (es) * | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| TWI664965B (zh) * | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
| CN108295072A (zh) * | 2015-12-09 | 2018-07-20 | 瑞阳(苏州)生物科技有限公司 | 尼达尼布防治眼部疾病的用途 |
| AU2017214475B2 (en) * | 2016-02-04 | 2024-03-28 | Ads Therapeutics Llc | Antibody-drug synergism technology for treating diseases |
| MX2018014869A (es) * | 2016-06-02 | 2019-09-13 | Cloudbreak Therapeutics Llc | Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal. |
| US11278546B2 (en) * | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| JP7030345B2 (ja) * | 2016-09-28 | 2022-03-07 | メディコン ファーマシューティカルズ，インコーポレイテッド | 眼の状態を処置する組成物および方法 |
| CN110072849A (zh) * | 2017-03-14 | 2019-07-30 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 |
-
2020
- 2020-09-10 AU AU2020346812A patent/AU2020346812A1/en active Pending
- 2020-09-10 JP JP2022507861A patent/JP2022547401A/ja active Pending
- 2020-09-10 EP EP20863255.4A patent/EP4027997A4/fr active Pending
- 2020-09-10 KR KR1020227010256A patent/KR20220061147A/ko active Search and Examination
- 2020-09-10 WO PCT/US2020/050150 patent/WO2021050692A2/fr unknown
- 2020-09-10 US US17/640,889 patent/US20220331310A1/en active Pending
- 2020-09-10 CA CA3146811A patent/CA3146811A1/fr active Pending
- 2020-09-10 CN CN202080061833.2A patent/CN114340618A/zh active Pending
- 2020-09-10 MX MX2022000468A patent/MX2022000468A/es unknown
- 2020-09-10 BR BR112021026662A patent/BR112021026662A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Panenka et al. | Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings | |
| JP2021113201A5 (fr) | ||
| TW201707700A (zh) | 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法 | |
| JP6750900B2 (ja) | 選択された抗コリン作用性双性イオンの使用 | |
| KR20100056569A (ko) | 운동성 질환에 걸린 환자의 치료 방법 | |
| JP4562911B2 (ja) | 遅発性ジスキネジア及び他の運動障害の治療方法 | |
| JP2019535760A (ja) | フルピルチンを用いた発達障害および／または発作性障害の処置方法 | |
| CN107949379A (zh) | L‑4‑氯代犬尿氨酸的治疗用途 | |
| JP6673924B2 (ja) | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール | |
| WO2021025988A1 (fr) | Protocoles et schémas posologiques pour traitement à l'aminostérol | |
| AU2022202508A1 (en) | Treatment of alopecia areata | |
| US11166922B2 (en) | Method for treating hyperhidrosis with dexmecamylamine | |
| JPWO2021050692A5 (fr) | ||
| EP1534289B2 (fr) | Antagonistes du recepteur a2a de l'adenosine destines au traitement du syndrome des jambes sans repos ou du myoclonus nocturne | |
| US20220331310A1 (en) | Methods for alleviating pterygium-associated worry about eye appearance | |
| JP7436524B2 (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| RU2469734C2 (ru) | Лечебное средство для лечения расстройств аккомодаций "stiak" | |
| Varshney et al. | Ropivacaine versus bupivacaine-lignocaine mixture in peribulbar block-A comparative study | |
| JP2004149480A (ja) | 経口又は経皮投与用の眼科疾患治療剤 | |
| Dayno et al. | 0612 Evaluation of Abuse Potential of the Narcolepsy Medication Pitolisant | |
| JP2023542137A (ja) | 白斑の局所処置 | |
| SU1734753A1 (ru) | Способ лечени дизурии гиперрефлекторного типа | |
| JPH05112450A (ja) | 緑内障性の視神経病の治療のための薬剤組成およびその治療法 | |
| TW201919597A (zh) | 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法 | |
| JPH08119858A (ja) | 自閉症治療剤 |